Powder: -20°C for 3 years | In solvent: -80°C for 1 year
TDN345 is a antagonist of Ca2+, for the treatment of vascular and senile dementia including Alzheimer's disease.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 6-8 weeks | $ 1,670.00 | |
50 mg | 6-8 weeks | $ 2,180.00 | |
100 mg | 6-8 weeks | $ 2,800.00 |
Description | TDN345 is a antagonist of Ca2+, for the treatment of vascular and senile dementia including Alzheimer's disease. |
In vitro | In the time-course study,TDN-345 treatment with 10 μM significantly increases the intracellular NGF content. TDN-345 induces NGF synthesis/secretion at the concentrations of 0.1 μM; statistically significant at 1 μM(ED50 of 0.88 μM)[1]. |
In vivo | When administered orally twice TDN-345 (0.1-1.0 mg/kg, p.o.) dose-dependently decreases the mortality and ischemic neurological deficit score, 60 min before ischemia and 90 min after recirculation. Additionally, In SHRSP, TDN-345 decreases the mortality and recurrence of stroke [2]. |
Molecular Weight | 468.58 |
Formula | C28H34F2N2O2 |
CAS No. | 134069-68-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
TDN345 134069-68-4 Others TDN 345 TDN-345 inhibitor inhibit